{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:37:26Z","timestamp":1779183446057,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.omtm.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T19:42:38Z","timestamp":1673898158000},"page":"284-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Systemic \u03b3-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C\/R5 mouse model"],"prefix":"10.1016","volume":"28","author":[{"given":"Young-Eun","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Baine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber N.","family":"Kempton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver C.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin","family":"Adegboye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Haile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle A.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellyn L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric R.","family":"Pozsgai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.01.004_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mus.26077","article-title":"Untangling the complexity of limb-girdle muscular dystrophies","volume":"58","author":"Liewluck","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.01.004_bib2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3233\/JND-150105","article-title":"The classification, natural history and treatment of the limb girdle muscular dystrophies","volume":"2","author":"Murphy","year":"2015","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2023.01.004_bib3","series-title":"Madame Curie Bioscience Database","article-title":"The sarcoglycans","author":"McNally","year":"2013"},{"key":"10.1016\/j.omtm.2023.01.004_bib4","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1002\/jcp.27907","article-title":"Prevalence, pathological mechanisms, and genetic basis of limb-girdle muscular dystrophies: a review","volume":"234","author":"Taghizadeh","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omtm.2023.01.004_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s13311-018-0648-x","article-title":"The limb-girdle muscular dystrophies: is treatment on the horizon?","volume":"15","author":"Chu","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtm.2023.01.004_bib6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.nmd.2017.02.011","article-title":"1st international workshop on clinical trial readiness for sarcoglycanopathies 15-16 november 2016, evry, France","volume":"27","author":"Marsolier","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.01.004_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ncl.2014.04.005","article-title":"The limb-girdle muscular dystrophies","volume":"32","author":"Wicklund","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.omtm.2023.01.004_bib8","doi-asserted-by":"crossref","first-page":"e0153095","DOI":"10.1371\/journal.pone.0153095","article-title":"Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D","volume":"11","author":"Fayssoil","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.01.004_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13395-020-00240-7","article-title":"The ties that bind: functional clusters in limb-girdle muscular dystrophy","volume":"10","author":"Barton","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtm.2023.01.004_bib10","doi-asserted-by":"crossref","first-page":"dmm040832","DOI":"10.1242\/dmm.040832","article-title":"A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping","volume":"13","author":"Demonbreun","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2023.01.004_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1083\/jcb.142.5.1279","article-title":"Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin","volume":"142","author":"Hack","year":"1998","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtm.2023.01.004_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2017.02.013","article-title":"Systemic AAV-mediated beta-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice","volume":"25","author":"Pozsgai","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.01.004_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.01.004_bib15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/med.21279","article-title":"Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers","volume":"33","author":"Mosqueira","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.omtm.2023.01.004_bib16","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1128\/JVI.07232-11","article-title":"Structural insight into the unique properties of adeno-associated virus serotype 9","volume":"86","author":"DiMattia","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.01.004_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.1999.0019","article-title":"Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer","volume":"1","author":"Cordier","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/brain\/awr342","article-title":"A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C","volume":"135","author":"Herson","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2023.01.004_bib19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtm.2019.04.007","article-title":"An AAV-SGCG dose-response study in a gamma-sarcoglycanopathy mouse model in the context of mechanical stress","volume":"13","author":"Israeli","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.01.004_bib20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/jpm10040258","article-title":"Of rAAV and men: from genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back","volume":"10","author":"Buscara","year":"2020","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.omtm.2023.01.004_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin alpha2 surrogates","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib23","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/hum.2019.006","article-title":"Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb infusion","volume":"30","author":"Mendell","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/hum.2016.141","article-title":"Comparison of serum rAAV serotype-specific antibodies in patients with duchenne muscular dystrophy, becker muscular dystrophy, inclusion body myositis, or GNE myopathy","volume":"28","author":"Zygmunt","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/hum.2017.062","article-title":"Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy","volume":"29","author":"Potter","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/gt.2015.80","article-title":"beta-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice","volume":"23","author":"Pozsgai","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/hum.2019.199","article-title":"Preclinical systemic delivery of adeno-associated \u03b1-sarcoglycan gene transfer for limb-girdle muscular dystrophy","volume":"32","author":"Griffin","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib29","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/jvi.70.5.3227-3234.1996","article-title":"Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors","volume":"70","author":"Ferrari","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.01.004_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/jvi.70.1.520-532.1996","article-title":"Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis","volume":"70","author":"Fisher","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.01.004_bib31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib32","first-page":"207","article-title":"LGMD. Identification, description and classification","volume":"39","author":"Angelini","year":"2020","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtm.2023.01.004_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11910-010-0119-1","article-title":"Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies","volume":"10","author":"Rocha","year":"2010","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.omtm.2023.01.004_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of duchenne muscular dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.01.004_bib35","doi-asserted-by":"crossref","first-page":"21785","DOI":"10.1074\/jbc.M101877200","article-title":"Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly","volume":"276","author":"Zhu","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.01.004_bib36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1097-2765(00)80083-0","article-title":"Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using delta-sarcoglycan gene transfer","volume":"1","author":"Holt","year":"1998","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtm.2023.01.004_bib37","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1017\/S1462399409001203","article-title":"Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects","volume":"11","author":"Sandon\u00e0","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.omtm.2023.01.004_bib38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.matbio.2018.01.014","article-title":"Regulation of fibrosis in muscular dystrophy","volume":"68-69","author":"Smith","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.omtm.2023.01.004_bib39","series-title":"Safety, \u03b2-Sarcoglycan Expression, and Functional Outcomes from Systemic Gene Transfer of rAAVrh74.MHCK7.hSGCB in Limb-Girdle Muscular Dystrophy Type 2E\/R4","author":"Rodino-Klapac","year":"2021"},{"key":"10.1016\/j.omtm.2023.01.004_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-5-45","article-title":"A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy","volume":"5","author":"Rodino-Klapac","year":"2007","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omtm.2023.01.004_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acn3.172","article-title":"AAV.Dysferlin overlap vectors restore function in dysferlinopathy animal models","volume":"2","author":"Sondergaard","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2023.01.004_bib42","doi-asserted-by":"crossref","DOI":"10.3791\/50183-v","article-title":"Evaluation of muscle function of the extensor digitorum longus muscle ex\u00a0vivo and tibialis anterior muscle in\u00a0situ in mice","author":"Hakim","year":"2013","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.omtm.2023.01.004_bib43","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.ajpath.2011.07.009","article-title":"mdx(\u2075cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice","volume":"179","author":"Beastrom","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtm.2023.01.004_bib44","first-page":"e50036","article-title":"Isometric and eccentric force generation assessment of skeletal muscles isolated from murine models of muscular dystrophies","author":"Moorwood","year":"2013","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.omtm.2023.01.004_bib45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/CIRCULATIONAHA.111.031716","article-title":"Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice","volume":"124","author":"Rafael-Fortney","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.omtm.2023.01.004_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nature07414","article-title":"Sarcolemma-localized nNOS is required to maintain activity after mild exercise","volume":"456","author":"Kobayashi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2023.01.004_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1601-183X.2004.00106.x","article-title":"Long-term individual housing in C57BL\/6J and DBA\/2 mice: assessment of behavioral consequences","volume":"4","author":"V\u00f5ikar","year":"2005","journal-title":"Genes Brain Behav."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:29:45Z","timestamp":1762421385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"alternative-id":["S2329050123000062"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.01.004","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic \u03b3-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C\/R5 mouse model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}